Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Aged 6 to 17 years and weight of at least 15 kg~* Meet DSM-IV criteria for of AD, established by chart review, clinical judgment and the Autism Diagnostic Interview- Revised (ADI-R) criteria~* Clinical Global Impressions Severity (CGI-S) score of \>4 (moderately ill)~* ABC Irritability subscale score of \>18~* Mental age of at least 18 months~* If female and sexually active, must agree to an acceptable method of birth control during the trial~* Medication free or adequate washout period (2-4 weeks prior to enrollment) of psychoactive drugs (anticonvulsants permitted for seizure management if dosage is stable for 4 weeks)~* Parent/guardian able to read and provide informed consent.~Exclusion Criteria~* Psychiatric disorder that is effectively managed by psychoactive medication (e.g. ADHD, MDD)~* Prior diagnosis or evidence of genetic or other disorder that may interfere with assessments (e.g. Fragile X syndrome, Fetal alcohol syndrome, history of very low birth weight) assessed by personal and family history, dysmorphology, and clinical judgment.~* Prior use of risperidone or aripiprazole for more than 2 weeks~* Seizure during the past 6 months~* History or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments during the trial including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, hematologic or immunologic disease as determined by the clinical judgment of the investigator~* Current suicidal or homicidal risk~* Positive urine pregnancy test at baseline~* Dependent on other substances, with the exception of nicotine or caffeine

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Risperidone (Type: ACTIVE_COMPARATOR): Atypical antipsychotic
- Aripiprazole (Type: ACTIVE_COMPARATOR): Atypical antipsychotic

Based on this trial design, predict the completion outcome and termination type (if applicable).